SCHEMBL30020165

SCHEMBL30020165

N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.50
DPP8 Q6V1X1 1/20 0.50
DPP9 Q86TI2 1/20 0.50
FOLH1 Q04609 1/20 0.49
RIMKLA Q8IXN7 1/20 0.49
NAALAD2 Q9Y3Q0 1/20 0.49
GRM8 O00222 1/20 0.48
GRM6 O15303 1/20 0.48
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GSR P00390 1/20 0.48
CYP1A2 P05177 1/20 0.48
GRIK1 P39086 1/20 0.48
GRM5 P41594 1/20 0.48
GRIA1 P42261 1/20 0.48
GRIA2 P42262 1/20 0.48
GRIA3 P42263 1/20 0.48
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48
SLC1A1 P43005 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30099544 1.00 DPP4 (0.50) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL30099651 1.00 DPP4 (0.50) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL30099554 1.00 DPP4 (0.50) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL30099498 1.00 DPP4 (0.50) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL31453847 1.00 DPP4 (0.50) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL31448323 0.97 FOLH1 (0.53) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL30607422 0.97 FOLH1 (0.53) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL31287182 0.97 DPP4 (0.53) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL28482649 0.97 DPP4 (0.53) DPP4DPP8DPP9FOLH1RIMKLA
SCHEMBL29379253 0.97 DPP4 (0.53) DPP4DPP8DPP9FOLH1RIMKLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12514939-B2 Stable radiopharmaceutical compositions and uses thereof ALPHA-9 ONCOLOGY, INC. (CA) 2026-01-06 US disclosed
US-20250255993-A1 STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF ALPHA-9 ONCOLOGY INC. (CA) 2025-08-14 US disclosed
CN-112125821-B Aqueous solution containing N-long-chain acyl acidic amino acid and/or salt thereof and method for producing same 味之素株式会社 2024-02-20 CN disclosed
CN-116004221-B New application of cyclic peptide, acridine labeled complex, preparation method and detection kit 湖南卓润生物科技有限公司 2023-12-19 CN disclosed
CN-116004221-A New application of cyclic peptide, acridine labeled complex, preparation method and detection kit 湖南卓润生物科技有限公司 2023-04-25 CN disclosed
CN-115261317-A Method for culturing cells, and kit and apparatus for the same 朱诺治疗学有限公司 2022-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250255993-A1 STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF RCN1, RABL6, QPCT DPP4 4320/4885DPP8 4343/4885DPP9 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.